Monday, March 09, 2015

Bayer loses in India over sorafenib

From a post in. Business Standard:


Natco raised its opposition on the grounds that the claims are drawn to polymorphic forms of Sorafenib, which is a known substance and not patentable under Section 3(c), Section 3(d) which says the mere discovery of a new form of a known substance that does not result in the enhancement of the known efficacy of the substance is not patentable, 3(e) which says a substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof or a process for producing such substance is not patentable, Section 25(1) (b)/(c) on lack of novelty, Section 25(1) (e) for lack of inventive step, among others.



Post a Comment

<< Home